BR112021003613A2 - conjugados de isoquinolina-esteróides e seus usos - Google Patents
conjugados de isoquinolina-esteróides e seus usos Download PDFInfo
- Publication number
- BR112021003613A2 BR112021003613A2 BR112021003613-0A BR112021003613A BR112021003613A2 BR 112021003613 A2 BR112021003613 A2 BR 112021003613A2 BR 112021003613 A BR112021003613 A BR 112021003613A BR 112021003613 A2 BR112021003613 A2 BR 112021003613A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- alkylene
- formula
- compound according
- alkyl
- Prior art date
Links
- 0 CN(C)[C@@](C(Nc1cc2ccncc2cc1)=O)c1ccc(CO*)cc1 Chemical compound CN(C)[C@@](C(Nc1cc2ccncc2cc1)=O)c1ccc(CO*)cc1 0.000 description 6
- QVSSDIRHTPRJOG-OAQYLSRUSA-N CCOCCc1ccc([C@@H](CN)C(Nc2cc3ccncc3cc2)=O)cc1 Chemical compound CCOCCc1ccc([C@@H](CN)C(Nc2cc3ccncc3cc2)=O)cc1 QVSSDIRHTPRJOG-OAQYLSRUSA-N 0.000 description 2
- FVVIAPXHQKNHDZ-UHFFFAOYSA-N CC(C)(C)OCc1ccc(C(C(Nc2cc3ccncc3cc2)=O)N(C)C)cc1 Chemical compound CC(C)(C)OCc1ccc(C(C(Nc2cc3ccncc3cc2)=O)N(C)C)cc1 FVVIAPXHQKNHDZ-UHFFFAOYSA-N 0.000 description 1
- UDLFKDHOQVRFSO-ZFQDKADRSA-N CC(C)(O[C@@H]1C[C@@H](C(C[C@@H](C([C@]2(C)C=C3)=CC3=O)F)[C@@]22F)[C@]3(C)C[C@@H]2O)O[C@]13C(COC(CCC(OCc1ccc(C(C(Nc2ccc(cncc3)c3c2)=O)N(C)C)cc1)=O)=O)=O Chemical compound CC(C)(O[C@@H]1C[C@@H](C(C[C@@H](C([C@]2(C)C=C3)=CC3=O)F)[C@@]22F)[C@]3(C)C[C@@H]2O)O[C@]13C(COC(CCC(OCc1ccc(C(C(Nc2ccc(cncc3)c3c2)=O)N(C)C)cc1)=O)=O)=O UDLFKDHOQVRFSO-ZFQDKADRSA-N 0.000 description 1
- NJXDFCQZYYGOBB-KNPNDIDRSA-N CC(C)(O[C@@H]1C[C@@H]([C@H](CCC([C@]2(C)C=C3)=CC3=O)[C@@]22F)[C@]3(C)C[C@@H]2O)O[C@]13C(COC(CCC(OCc1ccc(C(C(Nc2ccc(cncc3)c3c2)=O)N(C)C)cc1)=O)=O)=O Chemical compound CC(C)(O[C@@H]1C[C@@H]([C@H](CCC([C@]2(C)C=C3)=CC3=O)[C@@]22F)[C@]3(C)C[C@@H]2O)O[C@]13C(COC(CCC(OCc1ccc(C(C(Nc2ccc(cncc3)c3c2)=O)N(C)C)cc1)=O)=O)=O NJXDFCQZYYGOBB-KNPNDIDRSA-N 0.000 description 1
- NJXDFCQZYYGOBB-ZFYHEYBASA-N CC(C)(O[C@@H]1C[C@@H]([C@H](CCC([C@]2(C)C=C3)=CC3=O)[C@@]22F)[C@]3(C)C[C@@H]2O)O[C@]13C(COC(CCC(OCc1ccc([C@H](C(Nc2cc3ccncc3cc2)=O)N(C)C)cc1)=O)=O)=O Chemical compound CC(C)(O[C@@H]1C[C@@H]([C@H](CCC([C@]2(C)C=C3)=CC3=O)[C@@]22F)[C@]3(C)C[C@@H]2O)O[C@]13C(COC(CCC(OCc1ccc([C@H](C(Nc2cc3ccncc3cc2)=O)N(C)C)cc1)=O)=O)=O NJXDFCQZYYGOBB-ZFYHEYBASA-N 0.000 description 1
- UDLFKDHOQVRFSO-WCYUMXGZSA-N CC(C)(O[C@@H]1C[C@@H]([C@H](C[C@@H](C([C@]2(C)C=C3)=CC3=O)F)[C@@]22F)C3(C)CC2O)O[C@]13C(COC(CCC(OCc1ccc([C@H](C(Nc2cc3ccncc3cc2)=O)N(C)C)cc1)=O)=O)=O Chemical compound CC(C)(O[C@@H]1C[C@@H]([C@H](C[C@@H](C([C@]2(C)C=C3)=CC3=O)F)[C@@]22F)C3(C)CC2O)O[C@]13C(COC(CCC(OCc1ccc([C@H](C(Nc2cc3ccncc3cc2)=O)N(C)C)cc1)=O)=O)=O UDLFKDHOQVRFSO-WCYUMXGZSA-N 0.000 description 1
- KRWSXXJLQFPLHV-UHFFFAOYSA-N CC(C)OCCc1ccc(C(CN)C(Nc2cc3ccncc3cc2)=O)cc1 Chemical compound CC(C)OCCc1ccc(C(CN)C(Nc2cc3ccncc3cc2)=O)cc1 KRWSXXJLQFPLHV-UHFFFAOYSA-N 0.000 description 1
- NJHPUMBHAJTTRD-UHFFFAOYSA-N CC(C)c(cc1)ccc1C1=CC1(C)C(Nc1ccc(cncc2)c2c1F)=O Chemical compound CC(C)c(cc1)ccc1C1=CC1(C)C(Nc1ccc(cncc2)c2c1F)=O NJHPUMBHAJTTRD-UHFFFAOYSA-N 0.000 description 1
- TZJHKMUWBUTNCF-WHDOQBRNSA-N CC/C=C\C(/C=C(/CC[C@H]1[C@H](CC2)[C@](C)(C3)[C@]2(C(COC(CCC(OCc2ccc(C(C(Nc(cc4)cc5c4cncc5)=O)N(C)C)cc2)=O)=O)=O)O)\C[C@H]1[C@H]3O)=O Chemical compound CC/C=C\C(/C=C(/CC[C@H]1[C@H](CC2)[C@](C)(C3)[C@]2(C(COC(CCC(OCc2ccc(C(C(Nc(cc4)cc5c4cncc5)=O)N(C)C)cc2)=O)=O)=O)O)\C[C@H]1[C@H]3O)=O TZJHKMUWBUTNCF-WHDOQBRNSA-N 0.000 description 1
- ABTSXGREWJLROF-PSDZMVHGSA-N CC1(COC)C=CC([C@H](C(Nc2cc3ccncc3cc2)=O)N(C)C)=CC1 Chemical compound CC1(COC)C=CC([C@H](C(Nc2cc3ccncc3cc2)=O)N(C)C)=CC1 ABTSXGREWJLROF-PSDZMVHGSA-N 0.000 description 1
- LEZJGYYNDXFKMX-INIZCTEOSA-N CC[C@@H](CC(Nc1ccc(cncc2)c2c1F)=O)c1ccc(C(C)C)cc1 Chemical compound CC[C@@H](CC(Nc1ccc(cncc2)c2c1F)=O)c1ccc(C(C)C)cc1 LEZJGYYNDXFKMX-INIZCTEOSA-N 0.000 description 1
- BBEUPANYBWTPQV-UHFFFAOYSA-N COCCc1ccc(C(CN)C(Nc2cc3ccncc3cc2)=O)cc1 Chemical compound COCCc1ccc(C(CN)C(Nc2cc3ccncc3cc2)=O)cc1 BBEUPANYBWTPQV-UHFFFAOYSA-N 0.000 description 1
- CKGJSRYDLFAAQI-JQQKEGDNSA-N C[C@H](C1)[C@@]2(C(CO)=O)O[C@]2(C[C@@H]2O)[C@@H]1[C@H](CCC([C@]1(C)C=C3)=CC3=O)[C@]21F Chemical compound C[C@H](C1)[C@@]2(C(CO)=O)O[C@]2(C[C@@H]2O)[C@@H]1[C@H](CCC([C@]1(C)C=C3)=CC3=O)[C@]21F CKGJSRYDLFAAQI-JQQKEGDNSA-N 0.000 description 1
- UVBILYDOWRZXRA-UFHXJNBISA-N C[C@H](C1)[C@@]2(C(COC(c3cccc([C@H](C4)[C@]4(C)C(Nc4ccc(cncc5)c5c4)=O)c3)=O)=O)O[C@]2(C[C@@H]2O)[C@@H]1[C@H](CCC([C@]1(C)C=C3)=CC3=O)[C@]21F Chemical compound C[C@H](C1)[C@@]2(C(COC(c3cccc([C@H](C4)[C@]4(C)C(Nc4ccc(cncc5)c5c4)=O)c3)=O)=O)O[C@]2(C[C@@H]2O)[C@@H]1[C@H](CCC([C@]1(C)C=C3)=CC3=O)[C@]21F UVBILYDOWRZXRA-UFHXJNBISA-N 0.000 description 1
- IBOMAVLYGLPUTO-XOYSUSAYSA-N C[C@](C[C@@H]1O)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(C=C1)C3=CC1=O)[C@]2(C(COC(C(C1)C1C(OCc1ccc(C(C(Nc(cc2)cc3c2cncc3)=O)N(C)C)cc1)=O)=O)=O)O Chemical compound C[C@](C[C@@H]1O)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(C=C1)C3=CC1=O)[C@]2(C(COC(C(C1)C1C(OCc1ccc(C(C(Nc(cc2)cc3c2cncc3)=O)N(C)C)cc1)=O)=O)=O)O IBOMAVLYGLPUTO-XOYSUSAYSA-N 0.000 description 1
- IBOMAVLYGLPUTO-VOFWDNNGSA-N C[C@](C[C@@H]1O)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(C=C1)C3=CC1=O)[C@]2(C(COC(C(C1)C1C(OCc1ccc([C@H](C(Nc(cc2)cc3c2cncc3)=O)N(C)C)cc1)=O)=O)=O)O Chemical compound C[C@](C[C@@H]1O)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(C=C1)C3=CC1=O)[C@]2(C(COC(C(C1)C1C(OCc1ccc([C@H](C(Nc(cc2)cc3c2cncc3)=O)N(C)C)cc1)=O)=O)=O)O IBOMAVLYGLPUTO-VOFWDNNGSA-N 0.000 description 1
- HKKMDATZSXPGQM-FFUOIVMRSA-N C[C@](C[C@@H]1O)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(C=C1)C3=CC1=O)[C@]2(C(COC(CCC(OCc1ccc([C@H](C(Nc(cc2)cc3c2cncc3)=O)N(C)C)cc1)=O)=O)=O)O Chemical compound C[C@](C[C@@H]1O)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(C=C1)C3=CC1=O)[C@]2(C(COC(CCC(OCc1ccc([C@H](C(Nc(cc2)cc3c2cncc3)=O)N(C)C)cc1)=O)=O)=O)O HKKMDATZSXPGQM-FFUOIVMRSA-N 0.000 description 1
- JAIVNFYKOLPXHC-UHFFFAOYSA-N OC(c1cc(C(C2)(C3)C23C(Nc(cc2)cc3c2cncc3)=O)ccc1)=O Chemical compound OC(c1cc(C(C2)(C3)C23C(Nc(cc2)cc3c2cncc3)=O)ccc1)=O JAIVNFYKOLPXHC-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/0026—Oxygen-containing hetero ring cyclic ketals
- C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Botany (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862725941P | 2018-08-31 | 2018-08-31 | |
| US62/725,941 | 2018-08-31 | ||
| PCT/US2019/049195 WO2020047496A1 (en) | 2018-08-31 | 2019-08-30 | Isoquinoline-steroid conjugates and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021003613A2 true BR112021003613A2 (pt) | 2021-05-18 |
Family
ID=69639319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021003613-0A BR112021003613A2 (pt) | 2018-08-31 | 2019-08-30 | conjugados de isoquinolina-esteróides e seus usos |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11059789B2 (https=) |
| EP (1) | EP3843736A4 (https=) |
| JP (1) | JP7437384B2 (https=) |
| KR (1) | KR20210053301A (https=) |
| CN (1) | CN112638386A (https=) |
| AU (2) | AU2019328590B2 (https=) |
| BR (1) | BR112021003613A2 (https=) |
| MX (1) | MX2021002380A (https=) |
| SG (1) | SG11202101517PA (https=) |
| WO (1) | WO2020047496A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7437384B2 (ja) | 2018-08-31 | 2024-02-22 | アエリエ ファーマシューティカルズ インコーポレイテッド | イソキノリンステロイド抱合体およびその使用 |
| US12509469B2 (en) | 2019-08-07 | 2025-12-30 | Ripple Therapeutics Corporation | Compositions and methods for the treatment of pain and dependence disorders |
| US20230149387A1 (en) * | 2020-04-08 | 2023-05-18 | Aerie Pharmaceuticals, Inc. | Treatments |
| WO2021220061A2 (en) | 2020-05-01 | 2021-11-04 | Ripple Therapeutics Corporation | Heterodimer compositions and methods for the treatment of ocular disorders |
| JP2024516193A (ja) * | 2021-04-29 | 2024-04-12 | エアリー ファーマシューティカルズ インコーポレイテッド | 安定なイソキノリン－コルチコステロイドコンジュゲートおよびその使用 |
| EP4426712A4 (en) * | 2021-11-03 | 2026-04-08 | Ripple Therapeutics Corp | COMPOSITIONS SUITABLE FOR PROCESSING AND THEIR USE |
| CN115340472B (zh) * | 2022-09-19 | 2024-05-07 | 合肥工业大学 | 一种谷氨酸衍生物及其合成方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3193459A (en) * | 1955-07-01 | 1965-07-06 | Upjohn Co | Steroid hemisuccinate compositions and method for extemporaneous administration |
| US7470787B2 (en) * | 2005-07-11 | 2008-12-30 | Aerie Pharmaceuticals, Inc. | Isoquinoline compounds |
| US8455513B2 (en) * | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
| EP2109617A1 (en) * | 2007-02-05 | 2009-10-21 | Nicox S.A. | Nitric oxide releasing steroids |
| US8450344B2 (en) * | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
| EP3828172A1 (en) * | 2009-05-01 | 2021-06-02 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
| BR112015021388A2 (pt) * | 2013-03-08 | 2017-07-18 | Allergan Inc | conjugados esteroides de ciclosporina a |
| RU2015138891A (ru) * | 2013-03-08 | 2017-04-11 | Аллерган, Инк. | Конъюгаты антибиотиков, напрямую связанные со стероидными препаратами |
| ES2852377T3 (es) * | 2013-03-15 | 2021-09-13 | Aerie Pharmaceuticals Inc | Sales dimesilato de 4-(3-amino-1-(isoquinolin-6-ilamino)-1-oxopropan-2-il)bencilo, sus combinaciones con prostaglandinas y el uso de las mismas en el tratamiento de trastornos oculares |
| EP3500251A4 (en) * | 2016-08-19 | 2020-04-08 | Aerie Pharmaceuticals, Inc. | BETA AMINO ISOCHINOLINYL AMIDE COMPOUNDS |
| JP7437384B2 (ja) | 2018-08-31 | 2024-02-22 | アエリエ ファーマシューティカルズ インコーポレイテッド | イソキノリンステロイド抱合体およびその使用 |
-
2019
- 2019-08-30 JP JP2021510761A patent/JP7437384B2/ja active Active
- 2019-08-30 MX MX2021002380A patent/MX2021002380A/es unknown
- 2019-08-30 KR KR1020217008114A patent/KR20210053301A/ko not_active Abandoned
- 2019-08-30 CN CN201980056414.7A patent/CN112638386A/zh active Pending
- 2019-08-30 SG SG11202101517PA patent/SG11202101517PA/en unknown
- 2019-08-30 BR BR112021003613-0A patent/BR112021003613A2/pt not_active Application Discontinuation
- 2019-08-30 WO PCT/US2019/049195 patent/WO2020047496A1/en not_active Ceased
- 2019-08-30 AU AU2019328590A patent/AU2019328590B2/en not_active Ceased
- 2019-08-30 US US16/557,779 patent/US11059789B2/en active Active
- 2019-08-30 EP EP19853977.7A patent/EP3843736A4/en not_active Withdrawn
-
2021
- 2021-06-04 US US17/339,828 patent/US11691950B2/en active Active
-
2023
- 2023-07-12 AU AU2023204624A patent/AU2023204624A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3843736A1 (en) | 2021-07-07 |
| US11691950B2 (en) | 2023-07-04 |
| CN112638386A (zh) | 2021-04-09 |
| US11059789B2 (en) | 2021-07-13 |
| US20200071275A1 (en) | 2020-03-05 |
| MX2021002380A (es) | 2021-07-15 |
| AU2019328590A1 (en) | 2021-03-11 |
| SG11202101517PA (en) | 2021-03-30 |
| AU2023204624A1 (en) | 2023-08-03 |
| JP7437384B2 (ja) | 2024-02-22 |
| WO2020047496A1 (en) | 2020-03-05 |
| KR20210053301A (ko) | 2021-05-11 |
| AU2019328590B2 (en) | 2023-04-13 |
| JP2021535147A (ja) | 2021-12-16 |
| EP3843736A4 (en) | 2022-06-15 |
| US20210300874A1 (en) | 2021-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021003613A2 (pt) | conjugados de isoquinolina-esteróides e seus usos | |
| ES2275758T3 (es) | Compuestos de isoindol-imida, sus composiciones y sus usos. | |
| JP7050751B2 (ja) | Ｎｌｒｐ活性に関連する状態を処置するための化合物および組成物 | |
| JP6670841B2 (ja) | フェノール酸ｔｒｐｖ１アゴニストのプロドラッグ | |
| CN107105660A (zh) | 使用替唑尼特、其类似物或盐的前药的治疗组合物和治疗方法 | |
| CN119874561A (zh) | 带电的离子通道阻滞剂及其使用方法 | |
| JP2024096834A (ja) | （ｓ）－３－アミノ－４－（ジフルオロメチレニル）シクロペンタ－１－エン－１－カルボン酸の合成法 | |
| JP2022525856A (ja) | 荷電したイオンチャンネル遮断薬および使用方法 | |
| CN113924094A (zh) | 酯取代的离子通道阻滞剂及其使用方法 | |
| CN112384494B (zh) | 一种稠合三环γ-氨基酸衍生物的组合物及其制备 | |
| TW200848035A (en) | New combination 627 | |
| US20050245532A1 (en) | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their therapeutic application | |
| US20050245533A1 (en) | Inhibitors of the 11-beta-hydroxysteroid dehydrogenaseType 1 enzyme and their therapeutic application | |
| JP2021532183A (ja) | フェノール性ｔｒｐｖ１アゴニストのｐｅｇ化プロドラッグ | |
| ES2298358T3 (es) | Cristales de tosilato de suplatast. | |
| CN112118891A (zh) | 作为流感病毒复制抑制剂的稠和多环吡啶酮化合物 | |
| CN117362200A (zh) | 苯甲胺类化合物及其合成方法与应用 | |
| JP6010614B2 (ja) | 血清尿酸を低下させるための［１，２，４］チアジアジン１，１−ジオキサイド化合物 | |
| JP2024516193A (ja) | 安定なイソキノリン－コルチコステロイドコンジュゲートおよびその使用 | |
| RU2007132264A (ru) | Пролекарственные формы 1r, 2s-метоксамина, способ получения таких пролекарственных форм (варианты), фармацевтическая композиция, включающая их, и способ лечения недержания мочи посредством таких пролекарственных форм | |
| HK40059345A (en) | Pegylated prodrugs of phenolic trpv1 agonists | |
| HK40038397B (zh) | 一种稠合三环γ-氨基酸衍生物的组合物及其制备 | |
| EP1280523A2 (en) | Use of benzamide derivatives for the treatment of high ocular tension and glaucoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |